Review examines adoptive cellular therapies and immunoproteasome role in relapsed/refractory multiple myeloma
Review explores cellular therapies and immune system targeting for multiple myeloma
A systematic review discusses emerging evidence for adoptive cellular therapies (CAR T-cells, TCR-engineered T-cells) in relapsed/refractory…
Cellular therapies like CAR T-cells show promise for treating multiple myeloma, but severe side effects, high costs, and resistance limit th…
Case report describes diagnostic challenges in bilateral epithelioid sarcoma of the thigh
Imaging tests missed rare cancer in woman with thigh tumors, case report shows
A case report and literature review describes a 47-year-old woman with bilateral thigh masses where ultrasonography and MRI failed to provid…
Common scans missed a rare cancer in a woman with thigh tumors, proving that biopsies are vital when imaging results are unclear.
Envafolimab plus lenvatinib and capecitabine shows activity in resected biliary tract cancer
Combination therapy shows promise for preventing biliary tract cancer recurrence after surgery
A single-arm phase II trial in 28 patients with resected biliary tract cancer at high risk of recurrence found median disease-free survival …
A new three-drug combination helped 68% of high-risk biliary tract cancer patients stay cancer-free for a year after surgery, with 91% still…
Phase 3 trial of navitoclax plus ruxolitinib versus ruxolitinib alone in myelofibrosis posts results
Phase 3 trial tests navitoclax with ruxolitinib for myelofibrosis spleen volume
A phase 3 randomized controlled trial in 252 adults with myelofibrosis compared navitoclax plus ruxolitinib to ruxolitinib plus placebo.
A new drug combination aims to shrink painful enlarged spleens in myelofibrosis patients, but results from this large global trial are not y…
COVID-19 associated with increased lung cancer risk in current smokers; spike protein drives tumorigenesis in mice
Study finds link between COVID-19 and higher lung cancer risk in current smokers
A retrospective cohort analysis of 166,807 current smokers found COVID-19 was associated with increased lung cancer risk (RR 1.22; HR 1.50).
Current smokers with a history of COVID-19 face a higher risk of developing lung cancer, a link scientists traced to a specific virus protei…
CD8 PET imaging shows modest correlation with biopsy CD8 counts in solid tumor patients on immunotherapy
New imaging method shows modest link to immune cell counts in solid tumors
A Phase II prospective multicenter study of 49 patients with solid tumors receiving immune checkpoint blockade found a modest correlation (c…
A new PET scan shows a modest link to immune cell counts inside solid tumors, with stronger results in kidney cancer patients.
Locoregional CAR T-cell delivery reduces severe adverse events in high-grade glioma patients
Could a new way to deliver brain cancer therapy make it safer and more effective?
A meta-analysis of 14 clinical trials involving 194 high-grade glioma patients found locoregional CAR T-cell delivery was associated with re…
Delivering brain cancer therapy directly to the tumor instead of through the bloodstream cuts severe side effects by more than 60% and shows…
Report examines HPV-associated cancer incidence in American Indian and Alaska Native populations
Report examines HPV-related cancer rates in American Indian and Alaska Native communities
An observational report describes HPV-associated cancer incidence in American Indian and Alaska Native populations in the United States.
A new report tracks HPV-related cancer cases in American Indian and Alaska Native communities across the United States from 2013 to 2017.
Modeling study predicts human pharmacokinetics for TAK-500, an anti-CCR2 antibody-drug conjugate
Early modeling study predicts how a new cancer drug candidate might behave in humans
A preclinical and clinical modeling study used cynomolgus monkey data and human parental antibody data to simulate human pharmacokinetics fo…
A computer model predicts that a new cancer drug stays in the body longer as the dose increases, helping scientists plan safe first-in-human…
FDA Approves Zynyz (retifanlimab-dlwr) for Metastatic Anal Canal Cancer and Merkel Cell Carcinoma
FDA approves new drug Zynyz for two rare and aggressive types of cancer
The FDA has approved Zynyz, a PD-1 blocking antibody, for two indications: first-line treatment of inoperable locally recurrent or metastati…
FDA approves new drug Zynyz to treat two rare and aggressive cancers: advanced anal cancer and Merkel cell carcinoma.
FDA Approves Focinvez (fosaprepitant) for Prevention of Chemotherapy-Induced Nausea and Vomiting
FDA approves a new intravenous drug to help prevent nausea and vomiting from chemotherapy
The FDA has approved Focinvez, a substance P/NK1 receptor antagonist, for the prevention of acute and delayed nausea and vomiting associated…
FDA approves new IV drug to prevent severe nausea and vomiting from chemotherapy in adults and children 6 months and older.
Larger baseline tumor burden linked to shorter OS in rare cancers treated with nivolumab plus ipilimumab
Does tumor size predict how well immunotherapy works for rare cancers?
A secondary analysis of a phase 2 basket trial in 722 patients with rare/ultrarare malignancies found that larger baseline tumor burden was …
For rare cancers treated with immunotherapy, larger tumors at the start were linked to shorter overall survival, but not to how long patient…